Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-CD47 Polyclonal Antibody

Catalog #:   PHG17601 Specific References (84) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q08722
Overview

Catalog No.

PHG17601

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CD47 (Gln19-Pro139).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Leukocyte surface antigen CD47,CD47,Antigenic surface determinant protein OA3,IAP,Integrin-associated protein,Protein MER6,MER6

Purification

Purified by antigen affinity column.

Accession

Q08722

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with CD47 antibody (PHG17601) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 16 kDa
    Observed MW: 16 kDa
References

Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. PMID: 19144521

Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis. PMID: 31214201

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. PMID: 26512116

Monoclonal anti-CD47 interference in red cell and platelet testing. PMID: 30516833

Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. PMID: 30762908

Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. PMID: 29367423

Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas. PMID: 31383641

CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy. PMID: 29873856

Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPalpha Interaction as a Potential Cancer Immunotherapy. PMID: 32640189

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. PMID: 28378740

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. PMID: 31852716

TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. PMID: 27856600

Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. PMID: 30878596

Durable antitumor responses to CD47 blockade require adaptive immune stimulation. PMID: 27091975

Phagocytosis checkpoints as new targets for cancer immunotherapy. PMID: 31462760

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. PMID: 19632178

Blockade of CD47 or SIRPalpha: a new cancer immunotherapy. PMID: 32799682

Targeting the CD47-SIRPalpha signaling axis: current studies on B-cell lymphoma immunotherapy. PMID: 30226089

Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases. PMID: 32733941

CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. PMID: 29667847

Dysregulated integrin alphaVbeta3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis. PMID: 31534047

Targeting CD47 in Sezary syndrome with SIRPalphaFc. PMID: 30962222

Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases. PMID: 32061866

CD47: a potential immunotherapy target for eliminating cancer cells. PMID: 26830085

CD47 deficiency protects cardiomyocytes against hypoxia/reoxygenation injury by rescuing autophagic clearance. PMID: 31059044

Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. PMID: 31421198

SIRP/CD47 signaling in neurological disorders. PMID: 25795378

Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. PMID: 31879362

Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. PMID: 18657508

The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury. PMID: 30392076

CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway. PMID: 29321087

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. PMID: 21178137

[CD47 receptor as a primary target for cancer therapy]. PMID: 28537232

CD47 limits autophagy to promote acute kidney injury. PMID: 31480863

STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis., PMID:40529368

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014

SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma., PMID:40523887

Mechanism of EC-EXOs-Derived THBS3 Targeting CD47 to Regulate BMSCs Differentiation to Ameliorate Bone Loss., PMID:40514348

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837

Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351

Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521

Efferocytosis and its role in rheumatic diseases., PMID:40452369

Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716

CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525

CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082

The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557

A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266

USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682

Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617

CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148

Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397

Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435

The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156

Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459

Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma., PMID:40347051

Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT., PMID:40332470

Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602

TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254

Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909

N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109

Engineered Bacterial Outer Membrane Vesicles Hitchhiking on Neutrophils for Antibody Drug Delivery to Enhance Postoperative Immune Checkpoint Therapy., PMID:40287972

Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489

CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910

CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion., PMID:40255405

Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation., PMID:40251154

Successful targeting of multidrug-resistant tumors with bispecific antibodies., PMID:40248904

Nanobody Engineered and Photosensitiser Loaded Bacterial Outer Membrane Vesicles Potentiate Antitumour Immunity and Immunotherapy., PMID:40240911

The "don't eat me" signal CD47 is associated with microglial phagocytosis defects and autism-like behaviors in 16p11.2 deletion mice., PMID:40238451

Molecular and Immunometabolic Landscape of Erythrophagocytosis-induced Ferroptosis., PMID:40231500

An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272

High-Throughput Screening on Primary Tumor-Associated Microglia and Macrophages Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Partners for Immunotherapy in Glioblastoma., PMID:40196519

Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects., PMID:40187444

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)., PMID:40175391

Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells., PMID:40147800

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179

Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy., PMID:40138400

Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy., PMID:40136470

Regulating islet stress responses through CD47 activation., PMID:40133488

CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery., PMID:40087866

Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile., PMID:40084615

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CD47 Polyclonal Antibody [PHG17601]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only